Novel micelles based on amphiphilic branched PEG as carriers for fenretinide

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 6, 2012, Pages 880-890

  Orienti, Isabella ^a   Zuccari, Guendalina ^a   Falconi, Mirella ^a   Teti, Gabriella ^a   Illingworth, Nicola A ^b   Veal, Gareth J ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Amphiphilic macromolecules; Branched polyethylene glycol; Drug delivery; Fenretinide; Micellar complexes

Indexed keywords

AFTER-TREATMENT; AMPHIPHILIC MACROMOLECULES; AMPHIPHILICS; ANTI-TUMORS; AQUEOUS ENVIRONMENT; AQUEOUS SOLUBILITY; BRAIN CANCER; BRANCHED POLYETHYLENES; ELECTRONIC MICROSCOPY; FENRETINIDE; GLIOBLASTOMAS; HYDROCARBON CHAINS; INNER CORE; INTRACELLULAR CONCENTRATION; INTRAVENOUS ADMINISTRATION; MICELLAR COMPLEXES; NANOAGGREGATES; NEUROBLASTOMA CELL LINES;

CELL CULTURE; DRUG DELIVERY; HYDROCARBONS; MACROMOLECULES; METABOLITES; MOLECULAR BIOLOGY; PARTICLE SIZE ANALYSIS; POLYETHYLENE GLYCOLS;

MICELLES;

AMPHOPHILE; DRUG CARRIER; FENRETINIDE; MACROGOL;

AQUEOUS SOLUTION; ARTICLE; CELL VIABILITY; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SENSITIVITY; DRUG SOLUBILITY; ENDOCYTOSIS; EVALUATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MACROMOLECULE; MICELLE; NEUROBLASTOMA CELL; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLIZATION; DRUG DESIGN; FENRETINIDE; HUMANS; MICELLES; NANOCAPSULES; NEUROBLASTOMA; POLYETHYLENE GLYCOLS;

EID: 84864117619     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.10.008     Document Type: Article

References (38)

1. Linder L.H., Hossann M. Factors affecting drug release from liposomes. Curr Opin Drug Devel 2010, 13:111-123.
2. Torchilin V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 2004, 61:2549-2559.
3. Huynh N.T., Passirani C., Saulnier P., Benoit J.P. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 2009, 379:201-209.
4. Moinard-Checot D., Chevalier Y., Briançon S., Fessi H., Guinebretière S. Nanoparticles for drug delivery: review of the formulation and process difficulties illustrated by the emulsion-diffusion process. J Nanosci Nanotechnol 2006, 6:2664-2681.
5. Van de Manakker F., Vermonden T., Van Nostrum C.F., Hennink W.E. Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications. Biomacromolecules 2009, 10:3157-3175.
6. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24:1-16.
7. Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv 2010, 7:145-158.
8. Blanco E., Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 2009, 234:123-131.
9. Prabaharan M., Grailer J., Pilla S., Steeber D.A., Gong S. Amphiphilic multi-arm block copolymer based on hyperbranched polyester, poly(l-lactide) and poly(ethylene glycol) as a drug delivery carrier. Macromol Biosci 2009, 13:515-524.
10. Luo S., Xu J., Zhu Z., Wu C., Liu S. Phase transition behavior of unimolecular micelles with thermoresponsive poly(N-isopropylacrylamide) coronas. J Phys Chem B 2006, 110:9132-9139.
11. Kreutzer G., Ternat C., Nguyen T.Q., Plummer C.J.G., Månson J.A.E., Castelletto V., et al. Water-soluble, unimolecular containers based on amphiphilic multiarm star block copolymers. Macromolecules 2006, 39:4507-4516.
12. Bailon P., Won C.Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009, 6:1-16.
13. Veronese F.M., Mero A. The impact of PEGylation on biological therapies. Biodrugs 2008, 22:315-329.
14. Veronese F.M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 2005, 16:775-784.
15. Torchilin V.P. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2005, 2:319-327.
16. Xie J., Wang C.H. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm Res 2005, 22:2079-2090.
17. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
18. Camerini T., Mariani L., De Paolo G., Marubini E., Di Mauro M.G., Decensi A., et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001, 19:1664-1670.
19. Sogno I., Venè R., Ferrari N., De Censi A., Imperatori A., Noonan D.M., et al. Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol 2010, 75:2-14.
20. Hail N., Kim H.J., Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006, 11:1677-1694.
21. Corazzari M., Lovat P.E., Oliviero S., Di Sano F., Donnorso R.P., Redfern C.P., et al. Fenretinide: a p53-independent way to kill cancer cells. Biochem Biophys Res Commun 2005, 331:810-815.
22. Veronesi U., Mariani L., Decensi A., Formelli F., Camerini T., Miceli R. Fifteen-years results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006, 17:1065-1071.
23. Clarke N., Germain P., Altucci L., Gronemeyer H. Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 2004, 6:1-23.
24. Garaventa A., Luksch R., Lo Piccolo M.S., Cavadini E., Montaldo P.G., Pizzitola M.R., et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003, 9:2032-2039.
25. Villablanca J.G., Krailo M.D., Ames M.M., Reid J.M., Reaman G.H., Reynolds C.P. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006, 24:3423-3430.
26. Arpicco S., Dosio S., Bolognesi A., Lubelli C., Brusa P., Stella B., et al. Novel poly(ethylene glycol) derivatives for the preparation of ribosome-inactivating protein conjugates. Bioconjug Chem 2002, 13:757-765.
27. Morrison R, Boyd R.W. Organic chemistry 1992, 241-242. Prentice-Hall, Englewood Cliffs, NJ. 6th ed.
28. La S.B., Okano T., Kataoka K. Preparation and characterization of the micelle-forming polymeric drug indomethacin-incorporated poly(ethylene oxide)-poly(β-benzyl l-aspartate) block copolymer micelles. J Pharm Sci 1996, 85:85-90.
29. Orienti I., Zuccari G., Bergamante V., Carosio R., Gotti R., Cilli M., et al. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration. Biomacromolecules 2007, 8:3258-3262.
30. Orienti I., Zuccari G., Bergamante V., Mileo E., Lucarini M., Carosio R., et al. Amphiphilic poly(vinyl alcohol) derivatives as complexing agents for fenretinide. Biomacromolecules 2006, 7:3157-3163.
31. Formelli F., Clerici M., Campa T., Di Mauro M.G., Magni A., Mascotti G., et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993, 2036-42:11.
32. Veal G.J., Errington J., Redfern C.P.F., Pearson A.D.J., Boddy A.V. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochem Pharmacol 2002, 63:207-215.
33. Kubitschek H.E., Friske J.A. Determination of bacterial cell volume with the Coulter Counter. J. Bacteriol 1986, 168:1466-1467.
34. Maeda H., Wu J., Sawa T., Matsamura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
35. Strickley B. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004, 21:201-230.
36. Savić R., Eisenberg A., Maysinger D. Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions. J Drug Target 2006, 14:343-355.
37. Vasir J.K., Tambwekar K., Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003, 14:13-32.
38. Duncan R., Seymour L.C., Scarlett L., Lloyd J.B., Rejmanová P., Kopecek J. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta 1986, 880:62-71.